

# A Placebo-controlled Double-blind Study of the Effect of Finasteride on Prostatic Obstruction

British Journal of Urology

50, 551-554

DOI: [10.1111/j.1464-410x.1978.tb06210.x](https://doi.org/10.1111/j.1464-410x.1978.tb06210.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The action of bromocriptine on human detrusor muscle. Urological Research, 1980, 8, 207-9.	1.5	4
2	Phenoxybenzamine for benign prostatic obstruction review of 200 cases. Urology, 1981, 17, 542-546.	0.5	89
3	Effect of 17- $\beta$ -hydroxyprogesterone 17-n-caproate on urine flow. Urology, 1981, 17, 488-491.	0.5	4
4	The alpha-adrenergic blocking effect of prazosin on the human prostate. Urological Research, 1981, 9, 17-20.	1.5	59
5	Influence of the adrenergic nervous system on the lower urinary tract and its clinical implications. International Rehabilitation Medicine, 1982, 4, 37-43.	0.6	1
6	Adrenergic response of bladder muscle in prostatic obstruction. Urology, 1982, 20, 524-527.	0.5	121
7	Il Ruolo Della Fenossibenzamina Nel Trattamento Dell'Adenoma Della Prostata. Urologia, 1982, 49, 229-232.	0.3	2
8	Bladder Outflow Obstruction Treated with Phenoxybenzamine. British Journal of Urology, 1982, 54, 527-530.	0.1	111
9	Influence of the sympathetic nervous system on the lower urinary tract and its clinical implications. Neurourology and Urodynamics, 1982, 1, 129-148.	0.8	19
10	Prostatism: Clinical, radiological, and urodynamic aspects. Neurourology and Urodynamics, 1982, 1, 241-293.	0.8	73
11	Symptomatic treatment of benign prostatic obstruction with Nicergoline: A placebo controlled clinical study and urodynamic evaluation. Urological Research, 1982, 10, 131-4.	1.5	22
12	Candidin treatment of prostatism: A prospective double-blind placebo-controlled study. Urological Research, 1983, 11, 7-10.	1.5	19
13	Cavernosal Alpha-Blockade: A New Technique for Investigating and Treating Erectile Impotence. British Journal of Psychiatry, 1983, 143, 332-337.	1.7	478
14	Phenoxybenzamine in benign prostatic hypertrophy. Urology, 1983, 22, 351-352.	0.5	3
15	Ineffectiveness of phenoxybenzamine in treatment of benign prostatic hypertrophy A controlled study. Urology, 1983, 21, 474-478.	0.5	39
16	Effects of Prazosin in Patients with Benign Prostatic Obstruction. Journal of Urology, 1983, 130, 275-278.	0.2	230
18	Studio Randomizzato in Doppio Cieco Con Prazosin E Placebo Nel Trattamento Dell'Adenoma Prostatico. Urologia, 1983, 50, 122-130.	0.3	0
19	Alpha-Blockers in the Treatment of Benign Prostatic Hypertrophy: Physiological Basis and Review of the Problem. European Urology, 1984, 10, 306-310.	0.9	12

#	ARTICLE	IF	CITATIONS
20	Primary bladder neck obstruction. World Journal of Urology, 1984, 2, 191-195.	1.2	38
21	Characterization of Alpha1Adrenergic Receptors in Human Benign Prostatic Hyperplasia. Journal of Urology, 1984, 132, 1226-1229.	0.2	155
22	Candididin in Treatment of Benign Prostatic Hypertrophy. Journal of Urology, 1984, 132, 1235-1238.	0.2	6
23	&alpha;Adrenergic Blockade in the Diagnosis of Detrusor Instability Secondary to Infravesical Obstruction. Urologia Internationalis, 1984, 39, 312-313.	0.6	16
24	Alpha-Adrenoceptors and Muscarinic Receptors in the Isolated Human Prostate. Journal of Urology, 1985, 134, 1291-1298.	0.2	176
25	Bifluranol in the treatment of benign prostatic hyperplasia (BPH). Prostate, 1985, 7, 357-361.	1.2	5
26	Valutazione Clinica E in Vitro Degli Effetti Dell'Alfa-Bloccante Nicergolina Sul Collo Vescicale. Urologia, 1985, 52, 119-125.	0.3	0
27	Management of Urinary Incontinence in the Elderly. New England Journal of Medicine, 1985, 313, 800-805.	13.9	240
28	In vitro characterization of the Î±-adrenoceptors in human prostate. European Journal of Pharmacology, 1985, 107, 111-117.	1.7	134
29	The Present Role of Alpha-Adrenergic Blockers in the Treatment of Benign Prostatic Hypertrophy. Journal of Urology, 1986, 136, 1-4.	0.2	270
30	Alpha 2 Adrenergic Receptors in Hyperplastic Human Prostate: Identification and Characterization Using [ 3 H] Rauwolscine. Journal of Urology, 1986, 135, 1038-1042.	0.2	64
31	Sympathetic contribution to bladder outlet obstructions: Quantitative analysis of tissue catecholamine content. Neurourology and Urodynamics, 1986, 5, 573-577.	0.8	7
32	The Value of Permixon in Benign Prostatic Hypertrophy. British Journal of Urology, 1986, 58, 36-40.	0.1	72
33	Alpha <sub>1</sub> , Adrenergic Receptors in Canine Lower Genitourinary Tissues: Insight into Development and Function. Journal of Urology, 1987, 138, 979-983.	0.2	38
34	Alpha <sub>2</sub> Adrenergic Receptors in Canine Prostate: Biochemical and Functional Correlations. Journal of Urology, 1987, 137, 565-570.	0.2	31
35	Phenoxybenzamine in Prostatic Hypertrophy A Double-blind Study. British Journal of Urology, 1987, 59, 63-65.	0.1	18
36	Effect of prazosin on tissue of the human prostate with benign hypertrophy. Bulletin of Experimental Biology and Medicine, 1988, 106, 1129-1130.	0.3	0
37	Electrical and mechanical properties of the capsular smooth muscles of the rabbit prostate in relation to the actions of the Î±<sub>1</sub>-adrenoceptor blocker, YM&#x2611;2617. British Journal of Pharmacology, 1988, 93, 702-714.	2.7	17

#	ARTICLE	IF	CITATIONS
38	The stereospecificity of LY253352 for $\alpha_1$ -adrenoceptor binding sites in the brain and prostate. <i>British Journal of Pharmacology</i> , 1988, 95, 139-144.	2.7	19
39	Diabetic cystopathy. <i>The Journal of Diabetic Complications</i> , 1988, 2, 133-139.	0.2	47
40	The Pharmacology of Peripheral $\alpha_1$ and $\alpha_2$ -Adrenoceptors. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 1988, 7, 129-206.	0.7	6
41	Phenoxybenzamine in Benign Prostatic Obstruction-Reply. <i>JAMA - Journal of the American Medical Association</i> , 1988, 260, 2220.	3.8	0
42	Decreased Bone Density and Thyroxine-Reply. <i>JAMA - Journal of the American Medical Association</i> , 1988, 260, 2219.	3.8	0
43	$\alpha_1$ -Adrenergic Blockers. <i>Medical Clinics of North America</i> , 1988, 72, 427-440.	1.1	13
44	The Alpha Adrenergic Binding Properties of Terazosin in the Human Prostate Adenoma and Canine Brain. <i>Journal of Urology</i> , 1988, 140, 664-667.	0.2	34
45	The Effect of Electrocautery on Neurotransmitter Receptor Binding Assays in the Canine Prostate. <i>Journal of Urology</i> , 1988, 140, 668-671.	0.2	8
46	Nonsurgical treatment of benign prostatic hypertrophy. <i>World Journal of Urology</i> , 1989, 6, 209-214.	1.2	2
47	Contractile properties of human prostate adenomas and the development of infravesical obstruction. <i>Prostate</i> , 1989, 15, 105-114.	1.2	79
49	Nonoperative Management of Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 1989, 141, 1283-1289.	0.2	169
50	Benign prostatic hyperplasia: the best treatment.. <i>BMJ: British Medical Journal</i> , 1989, 299, 215-216.	2.4	38
51	Effects of an $\alpha_1$ -Adrenergic Blocker (Prazosin HCl) on Micturition Disturbances Associated with Benign Prostatic Hypertrophy. <i>Urologia Internationalis</i> , 1990, 45, 36-39.	0.6	2
52	Use of an $\alpha_1$ -Blocker, YM617, in the Treatment of Benign Prostatic Hypertrophy. <i>Journal of Urology</i> , 1990, 144, 908-911.	0.2	182
53	Autonomic Receptors in Human Prostate Adenomas. <i>Journal of Urology</i> , 1990, 143, 179-185.	0.2	111
54	Transurethral Hyperthermia for Benign Prostatic Hyperplasia: Preliminary Clinical Results. <i>Journal of Urology</i> , 1990, 143, 949-954.	0.2	86
55	A Dose Titration Study Evaluating Terazosin, a Selective, Once-a-Day $\alpha_1$ -Blocker for the Treatment of Symptomatic Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 1990, 144, 1393-1397.	0.2	66
56	Local Microwave Hyperthermia of Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 1990, 144, 913-917.	0.2	68

#	ARTICLE	IF	CITATIONS
57	The Efficacy of Transurethral Resection of the Prostate in Men with Moderate Symptoms of Prostatism. <i>Journal of Urology</i> , 1990, 143, 533-537.	0.2	196
58	Binding and functional properties of doxazosin in the human prostate adenoma and canine brain. <i>Prostate</i> , 1990, 16, 29-38.	1.2	7
59	Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. <i>Prostate</i> , 1990, 17, 1-7.	1.2	108
60	Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia. <i>Prostate</i> , 1990, 17, 75-84.	1.2	78
61	Efficacy of once-A-day terazosin in benign prostatic hyperplasia: A randomized, double-blind placebo-controlled clinical trial. <i>Prostate</i> , 1990, 17, 85-93.	1.2	67
62	Trattamento Sintomatico Dell'ipertrofia Prostatica Benigna Con Alfuzosine. <i>Urologia</i> , 1990, 57, 29-34.	0.3	0
63	Management of Benign Prostatic Hyperplasia. <i>Clinics in Geriatric Medicine</i> , 1990, 6, 69-84.	1.0	4
64	Medical management of benign prostatic hyperplasia. <i>Urology</i> , 1990, 36, 5-12.	0.5	11
65	Alfuzosin for treatment of benign prostatic hypertrophy. <i>Lancet</i> , The, 1991, 337, 1457-1461.	6.3	255
66	Current Concepts in the Treatment of Genitourinary Tract Disorders in the Older Individual. <i>Drugs and Aging</i> , 1991, 1, 176-193.	1.3	10
67	Endocrine treatment of benign prostatic hypertrophy: Current concepts. <i>Urology</i> , 1991, 37, 1-16.	0.5	12
68	Transurethral resection of prostate under sedation and local anesthesia (sedoanalgesia). <i>Urology</i> , 1991, 38, 113-118.	0.5	22
69	Too Stringent Patient Selection Criteria in a Clinical Trial of Alpha-Blockers Reduce the Value of the Results. <i>European Urology</i> , 1991, 20, 175-178.	0.9	1
70	Therapeutic Applications of Agents Interacting with $\alpha$ -Adrenoceptors. <i>Progress in Basic and Clinical Pharmacology</i> , 1991, 8, 180-220.	0.1	3
71	Binding Characteristics of $\alpha$ -Adrenoceptors in Bovine Prostate Using a Radioligand Binding Assay. <i>Journal of Pharmacobio-dynamics</i> , 1991, 14, 315-319.	0.5	1
74	Indoramin in the Treatment of Prostatic Bladder Outflow Obstruction. <i>British Journal of Urology</i> , 1991, 67, 499-501.	0.1	26
75	The Human Prostate Gland: A Histochemical and Immunohistochemical Study of Neuropeptides, Serotonin, Dopamine $\beta$ -Hydroxylase and Acetylcholinesterase in Autonomic Nerves and Ganglia. <i>British Journal of Urology</i> , 1991, 68, 53-61.	0.1	69
76	Autoradiographic localization of $\alpha$ -adrenoceptors in the dog prostate and urethra with $^3$ H-prazosin. <i>Neurourology and Urodynamics</i> , 1991, 10, 257-266.	0.8	6

#	ARTICLE	IF	CITATIONS
77	Alpha-adrenoceptor blockers in the treatment of benign prostatic hyperplasia. World Journal of Urology, 1991, 9, 36.	1.2	14
78	Efficacy and Side-Effects of Prazosin as a Symptomatic Treatment of Benign Prostatic Obstruction. Scandinavian Journal of Urology and Nephrology, 1991, 25, 15-19.	1.4	12
79	Alpha-Blockade for Benign Prostatic Hyperplasia. Journal of Endourology, 1991, 5, 83-87.	1.1	4
80	Transurethral microwave hyperthermia in benign prostatic hyperplasia. Optical Engineering, 1992, 31, 1917.	0.5	5
81	Medical treatment for benign prostatic hyperplasia.. BMJ: British Medical Journal, 1992, 304, 1198-1199.	2.4	20
82	Behcet's disease.. BMJ: British Medical Journal, 1992, 304, 1199-1200.	2.4	21
83	A Randomized, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic Hyperplasia. Journal of Urology, 1992, 148, 1467-1474.	0.2	324
84	<title>Transurethral microwave therapy of the prostate</title>. , 1992, , .		0
85	Binding characteristics of naftopidil and Î±1-adrenoceptor antagonists to prostatic Î±1-adrenoceptors in benign prostatic hypertrophy. Life Sciences, 1992, 50, 127-135.	2.0	32
86	10 Developments in the control of testicular function. Bailliere's Clinical Endocrinology and Metabolism, 1992, 6, 451-483.	1.0	26
87	Benign prostatic hyperplasia: pathogenesis and the role of medical management. Geriatric Nephrology and Urology, 1992, 2, 1-23.	0.4	3
88	Urinary Flow Rates in Patients with Benign Prostatic Hypertrophy following Treatment with Alfuzosin. British Journal of Urology, 1992, 70, 58-64.	0.1	48
89	A 12â€‘Week Placeboâ€‘controlled Doubleâ€‘blind Study of Prazosin in the Treatment of Prostatic Obstruction due to Benign Prostatic Hyperplasia. British Journal of Urology, 1992, 70, 285-294.	0.1	43
90	Placeboâ€‘controlled Study of Terazosin in the Treatment of Benign Prostatic Hyperplasia with 2â€‘Year Followâ€‘up. British Journal of Urology, 1992, 70, 10-16.	0.1	24
91	Panel IX: Alternatives to surgery for benign prostatic hyperplasia. Cancer, 1992, 70, 374-378.	2.0	7
92	Urinary Flow Rates in Patients with Benign Prostatic Hypertrophy following Treatment with Alfuzosin. British Journal of Urology, 1993, 72, 58-64.	0.1	0
93	Longâ€‘term Treatment of Benign Prostatic Hyperplasia with Alfuzosin: a 12â€‘18 Month Assessment. British Journal of Urology, 1993, 72, 615-620.	0.1	39
94	Finasteride. Drugs, 1993, 46, 177-208.	4.9	88

#	ARTICLE	IF	CITATIONS
95	Medical therapy for benign prostatic hyperplasia. <i>Urology</i> , 1993, 42, 483-501.	0.5	74
96	Protective Effect of R(â€”)1-(Benzo[b]thiophen-5-yl)-2-[2-(A&A-diethylamino)ethoxy]ethanol Hydrochloride (T-588), a Novel Cerebral Activator, against Experimental Cerebral Anoxia. <i>The Japanese Journal of Pharmacology</i> , 1993, 62, 297-304.	1.2	37
97	Medical Management of Benign Prostatic Hyperplasia: A Canine Model Comparing the in Vivo Efficacy of Alpha-1 Adrenergic Antagonists in the Prostate. <i>Journal of Urology</i> , 1993, 149, 395-399.	0.2	39
98	Î±1-Adrenoceptor Subtype in the Rat Prostate Is Preferentially the Î± Type. <i>The Japanese Journal of Pharmacology</i> , 1993, 62, 403-405.	1.2	4
99	Receptorial characterization of adrenergic neuroregulation of micturition, ejaculation and erection. An up-to-date review. <i>Urologia</i> , 1994, 61, 116-122.	0.3	0
101	Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: Assessment by urodynamic studies. <i>Prostate</i> , 1994, 25, 46-52.	1.2	35
102	Effect of terazosin on urine storage and voiding in the aging male with prostatism. <i>Neurourology and Urodynamics</i> , 1994, 13, 1-12.	0.8	24
103	Î±-Adrenoceptors. , 1994, 61, 1-64.		125
104	COMPARATIVE STUDY ON?1-ADRENOCEPTOR ANTAGONIST BINDING IN HUMAN PROSTATE AND AORTA. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1994, 21, 405-411.	0.9	53
105	Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. <i>British Journal of Urology</i> , 1994, 74, 579-584.	0.1	69
106	A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. <i>British Journal of Urology</i> , 1994, 74, 50-56.	0.1	129
107	Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: A combined analysis. <i>Urology</i> , 1994, 44, 46-51.	0.5	63
108	Morphometric quantitation of stromal human benign prostatic hyperplasia. <i>Urology</i> , 1994, 44, 64-70.	0.5	65
109	Functional identification of Î±1-adrenoceptor subtypes in human prostate: comparison with those in rat vas deferens and spleen. <i>European Journal of Pharmacology</i> , 1994, 265, 61-66.	1.7	36
110	Alpha1-adrenoceptors in human prostate: Characterization and binding characteristics of alpha1-antagonists. <i>Life Sciences</i> , 1994, 54, 1845-1854.	2.0	54
111	Benign Prostatic Hyperplasia. <i>Drugs</i> , 1994, 47, 66-81.	4.9	75
112	Reflections on alpha blockade therapy for benign prostatic hyperplasia. <i>British Journal of Urology</i> , 1995, 75, 265-270.	0.1	13
113	Use of recombinant Î±1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. <i>European Journal of Pharmacology</i> , 1995, 288, 201-207.	2.7	162

#	ARTICLE	IF	CITATIONS
114	Benign Prostatic Hyperplasia – Medical and Minimally Invasive Treatment Options. <i>New England Journal of Medicine</i> , 1995, 332, 99-110.	13.9	209
115	Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. <i>Urology</i> , 1995, 45, 406-413.	0.5	151
116	.alpha.- and .beta.-Adrenoceptors: From the Gene to the Clinic. 2. Structure-Activity Relationships and Therapeutic Applications. <i>Journal of Medicinal Chemistry</i> , 1995, 38, 3681-3716.	2.9	186
117	??1-Blockers vs 5??-Reductase Inhibitors in Benign Prostatic Hyperplasia. <i>Drugs and Aging</i> , 1995, 6, 388-396.	1.3	12
118	Randomised, placebo-controlled, double-blind clinical trial of $\hat{1}^2$ -sitosterol in patients with benign prostatic hyperplasia. <i>Lancet, The</i> , 1995, 345, 1529-1532.	6.3	264
119	Noradrenaline contractions of human prostate mediated by $\hat{1}\pm<sub>1c</sub>\hat{a}\epsilon(\hat{1}\pm<sub>1c</sub>\hat{a}\epsilon)$ adrenoceptor subtype. <i>British Journal of Pharmacology</i> , 1995, 115, 781-786.	2.7	148
120	Characterization of $\hat{1}\pm<sub>1</sub>\hat{a}\epsilon$ adrenoceptor subtypes in tension response of human prostate to electrical field stimulation. <i>British Journal of Pharmacology</i> , 1995, 115, 142-146.	2.7	43
121	Doxazosin in the Treatment of Benign Prostatic Hyperplasia in Normotensive Patients: A Multicenter Study. <i>Journal of Urology</i> , 1995, 154, 105-109.	0.2	176
122	Effect of Orchiectomy on the Alpha Adrenergic Contractile Response of Dog Prostate. <i>Journal of Urology</i> , 1995, 154, 1930-1933.	0.2	18
123	Placebo Controlled Double-blind Study to Test the Efficacy of the Aromatase Inhibitor Atamestane in Patients with Benign Prostatic Hyperplasia not Requiring Operation. <i>Journal of Urology</i> , 1995, 154, 399-401.	0.2	41
124	Doxazosin for the Treatment of Benign Prostatic Hyperplasia in Patients with Mild to Moderate Essential Hypertension: A Double-Blind, Placebo-Controlled, Dose-Response Multicenter Study. <i>Journal of Urology</i> , 1995, 154, 110-115.	0.2	183
125	A multicenter, randomized, double-blind, placebocontrolled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. <i>Urology</i> , 1996, 47, 335-342.	0.5	61
126	PROSTATISM. <i>Urologic Clinics of North America</i> , 1996, 23, 75-86.	0.8	19
127	Prostate Selectivity of Alpha-Blockers: From Receptor Biology to Clinical Medicine. <i>European Urology</i> , 1996, 29, 12-16.	0.9	6
128	Clinical Experiment Comparing 3 Pharmacological Treatments of Benign Prostatic Hypertrophy: Terazosin Vs. Finasteride Vs. Terazosin + Finasteride. <i>Urologia</i> , 1997, 64, 329-339.	0.3	0
129	Medical therapy for benign prostatic hyperplasia: the road ahead. <i>British Journal of Urology</i> , 1997, 79, 92-96.	0.1	5
130	Urodynamic Effects of Doxazosin in Men with Lower Urinary Tract Symptoms and Benign Prostatic Obstruction. <i>European Urology</i> , 1997, 32, 39-46.	0.9	16
131	A multicentric, placebo-controlled, double-blind clinical trial of $\beta$ -sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. <i>BJU International</i> , 1997, 80, 427-432.	1.3	154



#	ARTICLE	IF	CITATIONS
132	Prostatic $\hat{\pm}1$ -adrenoceptors and uroselectivity. , 1997, 30, 202-215.		127
133	$\hat{\pm}$ -Adrenergic approach in the medical management of benign prostatic hyperplasia. , 1997, 17, 523-535.		26
134	Does doxazosin affect prostatic growth?. , 1998, 35, 152-153.		1
135	Characterization of the muscarinic receptor mediating contraction of the dog prostate. Autonomic and Autacoid Pharmacology, 1998, 18, 205-212.	0.7	18
136	In vivo receptor binding of novel $\hat{\pm}1$ -adrenoceptor antagonists for treatment of benign prostatic hyperplasia. Life Sciences, 1998, 62, 1585-1589.	2.0	17
137	Ex vivo occupancy by tamsulosin of $\hat{\pm}1$ -adrenoceptors in rat tissues in relation to the plasma concentration. Life Sciences, 1998, 63, 2147-2155.	2.0	24
138	A Risk-Benefit Assessment of Treatment with Finasteride in Benign Prostatic Hyperplasia. Drug Safety, 1998, 18, 161-170.	1.4	12
139	Current Trends in Management of Men With Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia. Urology, 1998, 51, 1-7.	0.5	58
140	Voiding dysfunction in benign prostatic hyperplasia: trends, controversies and recent revelations. II. pathology and pathophysiology. Urology, 1998, 51, 73-82.	0.5	78
141	Phase III Multicenter Placebo-Controlled Study of Tamsulosin in Benign Prostatic Hyperplasia. Urology, 1998, 51, 892-900.	0.5	349
142	Alpha-Blockade Therapy for Benign Prostatic Hyperplasia: from a Nonselective to a More Selective Alpha1A-Adrenergic Antagonist. Urology, 1998, 51, 861-872.	0.5	75
143	THE MEDICAL MANAGEMENT OF LOWER URINARY TRACT SYMPTOMS AND BENIGN PROSTATIC HYPERPLASIA. Urologic Clinics of North America, 1998, 25, 555-569.	0.8	10
144	Medical Therapy and Quality of Life. European Urology, 1998, 34, 10-17.	0.9	22
145	Maximum Efficacy of Finasteride Is Obtained within 6 Months and Maintained over 6 Years. European Urology, 1998, 33, 312-317.	0.9	41
146	Tamsulosin: $\hat{\pm}1$ -Adrenoceptor Subtype-Selectivity and Comparison With Terazosin. The Japanese Journal of Pharmacology, 1998, 78, 331-336.	1.2	30
147	Benign Prostatic Hyperplasia in Older Men. Clinics in Geriatric Medicine, 1998, 14, 317-332.	1.0	6
148	Pharmacotherapy for benign prostatic hyperplasia - the potential for $\hat{\pm}1$ -adrenoceptor subtype-specific blockade. British Journal of Urology, 1998, 81, 34-47.	0.1	56
149	Clinical Pharmacology of $\alpha$ - <sub>1</sub> -Adrenoceptor Antagonists. European Urology, 1999, 36, 48-53.	0.9	17

#	ARTICLE	IF	CITATIONS
150	Subtype selective $\alpha_1$ -adrenoceptor antagonists for the treatment of benign prostatic hyperplasia. <i>Expert Opinion on Investigational Drugs</i> , 1999, 8, 2073-2094.	1.9	22
151	In vitro $\alpha_1$ -adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel $\alpha_1A$ -adrenoceptor selective antagonists. <i>British Journal of Pharmacology</i> , 1999, 127, 252-258.	2.7	77
152	Medical management of benign prostatic hyperplasia. , 1999, 9, 39-48.		17
153	Treatment of Benign Prostatic Enlargement with Alpha-blockers: an Updated Review. <i>Scandinavian Journal of Urology and Nephrology</i> , 1999, 33, 9-13.	1.4	3
154	A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the hypertension and BPH intervention trial (HABIT). <i>Clinical Therapeutics</i> , 1999, 21, 1732-1748.	1.1	44
155	NEW alpha 1-ADRENOCEPTOR ANTAGONIST, JTH-601, SHOWS MORE THAN 10 TIMES HIGHER AFFINITY FOR HUMAN PROSTATES THAN ARTERIES. <i>Journal of Urology</i> , 1999, 161, 1350-1354.	0.2	17
156	alpha-ADRENERGIC BLOCKADE IN CHILDREN WITH NEUROPATHIC AND NONNEUROPATHIC VOIDING DYSFUNCTION. <i>Journal of Urology</i> , 1999, 162, 1064-1067.	0.2	113
157	Transurethral Resection of the Prostate. <i>Southern Medical Journal</i> , 2000, 93, 1192-1196.	0.3	1
158	The autonomic and sensory innervation of the smooth muscle of the prostate gland: a review of pharmacological and histological studies. <i>Autonomic and Autacoid Pharmacology</i> , 2000, 20, 193-206.	0.7	102
159	Effect of JTH-601, a novel $\alpha_1$ -adrenoceptor antagonist, on prostate function in dogs. <i>European Journal of Pharmacology</i> , 2000, 394, 123-130.	1.7	10
160	Alpha adrenergic blockers in the treatment of benign hyperplasia of the prostate. , 2000, 32, 67-71.		23
161	The clinical role of $\alpha_1$ -blockers in the treatment of benign prostatic hyperplasia. <i>Current Urology Reports</i> , 2000, 1, 97-102.	1.0	7
162	Transurethral Microwave Thermotherapy: An Alternative to Medical Management in Patients with Benign Prostatic Hyperplasia?. <i>Journal of Endourology</i> , 2000, 14, 661-669.	1.1	6
163	Chapter 20. Toward the development of $\alpha_1a$ adrenergic receptor antagonists. <i>Annual Reports in Medicinal Chemistry</i> , 2000, 35, 221-230.	0.5	17
164	Terazosin, doxazosin, and prazosin: current clinical experience. <i>Urology</i> , 2001, 58, 49-54.	0.5	63
165	Alpha adrenoceptor antagonists in the year 2000: is there anything new?. <i>Current Opinion in Urology</i> , 2001, 11, 9-16.	0.9	32
166	Comparison of prazosin, terazosin and tamsulosin: Functional and binding studies in isolated prostatic and vascular human tissues. <i>Prostate</i> , 2001, 47, 231-238.	1.2	5
167	Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia. <i>International Urology and Nephrology</i> , 2001, 33, 407-412.	0.6	20

#	ARTICLE	IF	CITATIONS
168	The use of $\alpha_1$ -adrenoceptor antagonists in lower urinary tract disease. Expert Opinion on Pharmacotherapy, 2002, 3, 167-172.	0.9	24
170	A modern rationale for the use of phenoxybenzamine in urinary tract disorders and other conditions. Clinical Therapeutics, 2002, 24, 851-861.	1.1	28
172	Cholinergic innervation and function in the prostate gland. , 2002, 94, 93-112.		98
173	Structure-Activity relationships among novel phenoxybenzamine-Related $\alpha_2$ -Chloroethylamines. Bioorganic and Medicinal Chemistry, 2002, 10, 1291-1303.	1.4	8
174	The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Current Prostate Reports, 2003, 1, 30-35.	0.1	0
175	The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Current Urology Reports, 2003, 4, 276-281.	1.0	2
176	Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Contemporary Clinical Trials, 2003, 24, 224-243.	2.0	86
177	Heat versus drugs in the treatment of benign prostatic hyperplasia. BJU International, 2003, 91, 131-137.	1.3	6
178	Pharmacological Characterization of Isolated Human Prostate. Journal of Urology, 2003, 170, 1032-1038.	0.2	32
179	Drug Treatments for Lower Urinary Tract Symptoms Secondary to Bladder Outflow Obstruction. Drugs, 2003, 63, 1947-1962.	4.9	20
180	Apoptotic impact of $\alpha_1$ -blockers on prostate cancer growth: A myth or an inviting reality?. Prostate, 2004, 59, 91-100.	1.2	37
181	Changing aspects in the evaluation and treatment of patients with benign prostatic hyperplasia. Medical Clinics of North America, 2004, 88, 281-308.	1.1	10
182	$\alpha_1$ -Adrenoceptor Subtype Selectivity and Lower Urinary Tract Symptoms. Mayo Clinic Proceedings, 2004, 79, 1423-1434.	1.4	36
183	Transurethral microwave thermotherapy for treatment of benign prostatic hyperplasia. The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender, 2004, 1, 182-190.	0.3	1
184	Efficacy of Low-Dose Tamsulosin on Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia. Clinical Drug Investigation, 2004, 24, 41-47.	1.1	38
185	Noninvasive Management of Lower Urinary Tract Symptoms and Sexual Dysfunction Associated With Benign Prostatic Hyperplasia in the Primary Care Setting. Comprehensive Therapy, 2005, 31, 194-208.	0.2	2
186	Controlled-release doxazosin in the treatment of benign prostatic hyperplasia. Prostate Cancer and Prostatic Diseases, 2005, 8, 375-380.	2.0	7
187	Comparison of phenoxybenzamine to sodium nitroprusside in infants undergoing surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2005, 19, 54-59.	0.6	41

#	ARTICLE	IF	CITATIONS
189	Management of Benign Prostate Hyperplasia: An Overview of $\alpha$ -Adrenergic Antagonist. Biological and Pharmaceutical Bulletin, 2006, 29, 1554-1558.	0.6	10
190	The role of alfuzosin in the treatment of benign prostate hyperplasia and acute urinary retention. Aging Health, 2006, 2, 363-369.	0.3	0
191	Emerging drug therapies for benign prostatic hyperplasia. Expert Opinion on Emerging Drugs, 2006, 11, 111-123.	1.0	56
192	SERENDIPITY IN UROLOGY. BJU International, 2008, 101, 415-416.	1.3	2
193	The Influence of Alpha1-Adrenoreceptors on Neuropeptide Release from Primary Sensory Neurons of the Lower Urinary Tract. European Urology, 2007, 52, 901-908.	0.9	52
194	Tamsulosin MR and OCAS (modified release and oral controlled absorption system): current therapeutic uses. Expert Opinion on Pharmacotherapy, 2008, 9, 813-824.	0.9	4
196	Identification of $\alpha$ 1-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens. European Journal of Pharmacology, 2009, 602, 388-394.	1.7	9
197	Subtypes of $\alpha$ 1-adrenoceptors in BPH: future prospects for personalized medicine. Nature Reviews Urology, 2009, 6, 44-53.	1.4	26
198	Established Medical Therapy for Benign Prostatic Hyperplasia. Urologic Clinics of North America, 2009, 36, 443-459.	0.8	86
199	The Forefront for Novel Therapeutic Agents Based on the Pathophysiology of Lower Urinary Tract Dysfunction: $\alpha$ -Blockers in the Treatment of Male Voiding Dysfunction "How Do They Work and Why Do They Differ in Tolerability?". Journal of Pharmacological Sciences, 2010, 112, 151-157.	1.1	39
200	Alpha-Blockers and Intraoperative Floppy Iris Syndrome: Ophthalmic Adverse Events Following Cataract Surgery. Current Urology Reports, 2010, 11, 242-248.	1.0	7
201	A facile enantioselective synthesis of enantiomerically pure (R)-phenoxybenzamine hydrochloride using the hydrolytic kinetic resolution method. Tetrahedron: Asymmetry, 2010, 21, 2825-2829.	1.8	12
202	Targeting the chromosome partitioning protein ParA in tuberculosis drug discovery. Journal of Antimicrobial Chemotherapy, 2010, 65, 2347-2358.	1.3	27
203	Effect of Shifting from Combination Therapy to Monotherapy of $\alpha$ -Blockers or 5 $\alpha$ -Reductase Inhibitors on Prostate Volume and Symptoms in Patients with Benign Prostatic Hyperplasia. Korean Journal of Urology, 2011, 52, 681.	1.2	6
204	Sympathomimetic and sympatholytic drugs. , 0, , 648-665.		0
205	$\alpha$ 1-Adrenoceptor Subtypes in Bovine Prostate. Journal of Pharmacy and Pharmacology, 2011, 44, 727-730.	1.2	19
206	Animal Models for Benign Prostatic Hyperplasia. Handbook of Experimental Pharmacology, 2011, , 69-79.	0.9	17
207	$\alpha$ -Blockers for benign prostatic hyperplasia. Current Opinion in Urology, 2012, 22, 7-15.	0.9	83

#	ARTICLE	IF	CITATIONS
208	Alpha adrenoreceptor antagonists “ have we reached the optimum balance of safety/efficacy?. Drug Discovery Today: Therapeutic Strategies, 2012, 9, e27-e33.	0.5	1
210	Advances in the design and discovery of drugs for the treatment of prostatic hyperplasia. Expert Opinion on Drug Discovery, 2013, 8, 1013-1027.	2.5	10
211	Alteration of Loperamide-Induced Prostate Relaxation in High-Fat Diet-Fed Rats. Scientific World Journal, The, 2014, 2014, 1-6.	0.8	1
212	Phenoxybenzamine Is Neuroprotective in a Rat Model of Severe Traumatic Brain Injury. International Journal of Molecular Sciences, 2014, 15, 1402-1417.	1.8	16
213	Landmarks in BPH“from aetiology to medical and surgical management. Nature Reviews Urology, 2014, 11, 118-122.	1.9	11
214	Cardiac Alpha<sub>1</sub>-Adrenergic Receptors: Novel Aspects of Expression, Signaling Mechanisms, Physiologic Function, and Clinical Importance. Pharmacological Reviews, 2014, 66, 308-333.	7.1	168
215	Lower urinary tract symptoms in men. BMJ, The, 2014, 349, g4474-g4474.	3.0	50
216	Correlation Analysis between Visceral Manifestation Theories on Xuanfa and Effect of Adrenergic Receptors. Chinese Herbal Medicines, 2014, 6, 85-92.	1.2	4
217	Effectiveness of 'on demand' silodosin in the treatment of premature ejaculation in patients dissatisfied with dapoxetine: a randomized control study. Central European Journal of Urology, 2016, 69, 280-284.	0.2	4
218	Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia. Urologic Clinics of North America, 2016, 43, 311-323.	0.8	37
219	Medical Treatment of the“Large Prostate. , 2018, , 53-73.		0
221	Is Tamsulosin Linked to Dementia in the Elderly?. Current Urology Reports, 2018, 19, 69.	1.0	7
222	The affinity and selectivity of “adrenoceptor antagonists, antidepressants, and antipsychotics for the human “1A, “1B, and “1D“adrenoceptors. Pharmacology Research and Perspectives, 2020, 8, e00602.	1.1	26
223	Re: Sachin Malde, Roland Umbach, Jessica R. Wheeler, et al. A Systematic Review of Patients“ Values, Preferences, and Expectations for the Diagnosis and Treatment of Male Lower Urinary Tract Symptoms. Eur Urol 2021;79:796“809. European Urology, 2021, 79, e170-e171.	0.9	2
224	Pharmacological Treatment of Benign Prostatic Hypertrophy. Clinical Practice in Urology, 1984, , 135-152.	0.2	1
225	Current Models and Their Relation to Human Disease. , 1983, , 215-228.		5
226	Changes in Adrenergic Receptors in Bladder Outlet Obstruction. , 1983, , 410-413.		3
227	Pharmacological Management of Outlet Obstruction. , 1983, , 419-424.		4

#	ARTICLE	IF	CITATIONS
228	The Anatomical Objectives of Operation. , 1983, , 797-805.		1
229	Evaluation and Nonsurgical Management of Benign Prostatic Hyperplasia. , 2012, , 2611-2654.e8.		17
230	ALPHA BLOCKADE FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA. Urologic Clinics of North America, 1995, 22, 375-386.	0.8	44
231	Embryologic Development of the Prostate. Urologic Clinics of North America, 1990, 17, 487-493.	0.8	23
232	Epidemiology and Natural History of Benign Prostatic Hyperplasia. Urologic Clinics of North America, 1990, 17, 495-507.	0.8	194
233	Clinical Manifestations of Benign Prostatic Hyperplasia and Indications for Therapeutic Intervention. Urologic Clinics of North America, 1990, 17, 509-516.	0.8	81
234	Alpha-Adrenergic Blockers for the Treatment of Benign Prostatic Hyperplasia. Urologic Clinics of North America, 1990, 17, 641-649.	0.8	87
235	Doxazosin in the Treatment of Benign Prostatic Hyperplasia in Normotensive Patients. Journal of Urology, 1995, , 105-109.	0.2	6
236	Doxazosin for the Treatment of Benign Prostatic Hyperplasia in Patients with Mild to Moderate Essential Hypertension. Journal of Urology, 1995, , 110-115.	0.2	7
237	Placebo Controlled Double-blind Study to Test the Efficacy of the Aromatase Inhibitor Atamestane in Patients with Benign Prostatic Hyperplasia not Requiring Operation. Journal of Urology, 1995, 154, 399-401.	0.2	14
239	alpha-ADRENERGIC BLOCKADE IN CHILDREN WITH NEUROPATHIC AND NONNEUROPATHIC VOIDING DYSFUNCTION. Journal of Urology, 1999, 162, 1064-1067.	0.2	27
240	Sexual dysfunction in patients with benign prostatic hyperplasia. Current Opinion in Urology, 1999, 9, 9-14.	0.9	7
241	Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH). Therapeutics and Clinical Risk Management, 2007, 3, 181-196.	0.9	9
242	Medical Management for Benign Prostatic Hyperplasia. Korean Journal of Urology, 2007, 48, 233.	0.2	5
246	Long Term Effectiveness of Doxazosin in Men with Lower Urinary Tract Symptoms Suggesting of Benign Prostatic Hyperplasia. Korean Journal of Urology, 2008, 49, 1003.	0.2	0
247	Non-Hormonal treatment of BPH/BOO. Indian Journal of Urology, 2014, 30, 194.	0.2	2
248	EFFECTS OF 6-HYDROXYDOPAMINE ON NEUROGENIC BLADDER DYSFUNCTION THE FORTH REPORT. Japanese Journal of Urology, 1982, 73, 1410-1415.	0.0	0
249	The Pharmacology of Urinary Incontinence. , 1984, , 419-440.		2

#	ARTICLE	IF	CITATIONS
250	Therapeutic Applications of Agents Interacting with alpha-1 Adrenergic Receptors. Receptors, 1987, , 477-500.	0.2	0
251	Is Pharmacotherapy for Benign Prostatic Hyperplasia an Alternative?. , 1992, , 155-171.		0
252	Tumoren des Urogenitaltraktes. , 1992, , 398-535.		0
253	Î±-Adrenergic Blockade in the Treatment of Benign Prostatic Hyperplasia. , 1993, , 173-182.		0
255	The Natural History of Benign Prostatic Hyperplasia. , 1994, , 39-48.		0
256	The Use of Pharmacologic Agents for Benign Prostatic Hyperplasia. , 1994, , 193-204.		0
257	Is Pharmacotherapy a Satisfactory Alternative Treatment for Benign Prostatic Hyperplasia?. , 1994, , 189-212.		0
259	Medical Management of Benign Prostatic Hyperplasia. , 2020, , 21-42.		1
260	The response of the benign hypertrophied prostate to endocrine therapy. , 1983, , 263-280.		0
261	Physiology and Pharmacology of the Prostate. , 2020, , 127-150.		1
264	Urethral pressure profile and hemodynamic effects of phenoxybenzamine and prazosin in non-sedated male beagle dogs. Canadian Journal of Veterinary Research, 2003, 67, 30-8.	1.1	26
265	The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia. Reviews in Urology, 2006, 8, 183-9.	0.9	14
266	The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia. Reviews in Urology, 2006, 8 Suppl 4, S3-9.	0.9	14
267	New Treatments for Benign Prostatic Hyperplasia: Prostatectomy and other forms of therapy. Canadian Family Physician, 1991, 37, 935-9.	0.1	0
268	Alpha blockers for the treatment of benign prostatic hyperplasia. Reviews in Urology, 2007, 9, 181-90.	0.9	73
269	The anti-hypertensive drug prazosin induces apoptosis in the medullary thyroid carcinoma cell line TT. Anticancer Research, 2015, 35, 31-38.	0.5	13
270	Role of alpha blockers in treating obstructive uropathy. Urologie Pro Praxi, 2021, 21, 150-154.	0.0	1
271	Pharmakologische Therapie. , 2022, , 85-103.		0

#	ARTICLE	IF	CITATIONS
272	RECENT PROGRESS IN THE PHARMACOTHERAPY OF DISEASES OF THE LOWER URINARY TRACT. European Journal of Medicinal Chemistry, 1995, 30, 269s-298s.	2.6	4
273	EXPANDING ROLE OF ALPHA ADRENOCEPTOR BLOCKADE IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA. International Journal of Clinical Practice, 1998, 52, 402-407.	0.8	6
275	Pharmacological Therapy. , 2023, , 81-98.		0